Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial by Prince, H Miles, Prof, Kim, Youn H, Prof, Horwitz, Steven M, MD, Dummer, Reinhard, Prof, Scarisbrick, Julia, MD, Quaglino, Pietro, Prof, Zinzani, Pier Luigi, Prof, Wolter, Pascal, MD, Sanches, Jose A, PhD, Ortiz-Romero, Pablo L, Prof, Akilov, Oleg E, MD, Geskin, Larisa, MD, Trotman, Judith, MD, Taylor, Kerry, MBBS, Dalle, Stephane, Prof, Weichenthal, Michael, Prof, Walewski, Jan, Prof, Fisher, David, MD, Dréno, Brigitte, Prof, Stadler, Rudolf, Prof, Feldman, Tatyana, MD, Kuzel, Timothy M, Prof, Wang, Yinghui, MS, Palanca-Wessels, Maria Corinna, MD, Zagadailov, Erin, PharmD, Trepicchio, William L, PhD, Zhang, Wenwen, PhD, Lin, Hui-Min, PhD, Liu, Yi, PhD, Huebner, Dirk, MD, Little, Meredith, MPH, Whittaker, Sean, Prof, Duvic, Madeleine, Prof

Get full text

Health policy and system support to optimise community health worker programmes: an abridged WHO guideline by Cometto, Giorgio, Ford, Nathan, Pfaffman-Zambruni, Jerome, Akl, Elie A, Lehmann, Uta, McPake, Barbara, Ballard, Madeleine, Kok, Maryse, Najafizada, Maisam, Olaniran, Abimbola, Ajuebor, Onyema, Perry, Henry B, Scott, Kerry, Albers, Bianca, Shlonsky, Aron, Taylor, David

Get full text